1
|
Washington SL, Lonergan PE, Cowan JE, Zhao S, Broering JM, Palmer NR, Hicks C, Cooperberg MR, Carroll PR. Ten-year work burden after prostate cancer treatment. Cancer Med 2023; 12:19234-19244. [PMID: 37724617 PMCID: PMC10557888 DOI: 10.1002/cam4.6530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 08/30/2023] [Accepted: 09/02/2023] [Indexed: 09/21/2023] Open
Abstract
INTRODUCTION We aim to characterize the magnitude of the work burden (weeks off from work) associated with prostate cancer (PCa) treatment over a 10-year period after PCa diagnosis and identify those at greatest risk. MATERIALS AND METHODS We identified men diagnosed with PCa treated with radical prostatectomy, radiation therapy, or active surveillance/watchful waiting within CaPSURE. Patients self-reported work burden and SF36 general health scores via surveys before and 1,3,5, and 10 years after treatment. Using multivariate repeated measures generalized estimating equation modeling we examined the association between primary treatment with risk of any work weeks lost due to care. RESULTS In total, 6693 men were included. The majority were White (81%, 5% Black, and 14% Other) with CAPRA low- (60%) or intermediate-risk (32%) disease and underwent surgery (62%) compared to 29% radiation and 9% active surveillance. Compared to other treatments, surgical patients were more likely to report greater than 7 days off work in the first year, with relatively less time off over time. Black men (RR 0.64, 95% CI 0.54-0.77) and those undergoing radiation (vs. surgery, RR 0.46, 95% CI 0.41-0.51) were less likely to report time off from work over time. Mean baseline GH score (73 [SD 18]) was similar between race and treatment groups, and stable over time. CONCLUSIONS The work burden of cancer care continued up to 10 years after treatment and varied across racial groups and primary treatment groups, highlighting the multifactorial nature of this issue and the call to leverage greater resources for those at greatest risk.
Collapse
Affiliation(s)
- Samuel L. Washington
- Department of Urology, Helen Diller Family Comprehensive Cancer CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
- Department of Epidemiology & BiostatisticsUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Peter E. Lonergan
- Department of UrologySt. James's HospitalDublinIreland
- Department of Surgery, School of MedicineTrinity College DublinDublinIreland
| | - Janet E. Cowan
- Department of Urology, Helen Diller Family Comprehensive Cancer CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Shoujun Zhao
- Department of Urology, Helen Diller Family Comprehensive Cancer CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | | | - Nynikka R. Palmer
- Department of Urology, Helen Diller Family Comprehensive Cancer CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
- Department of MedicineUniversity of CaliforniaSan FranciscoCaliforniaUSA
- Division of General Internal MedicineZuckerberg San Francisco General HospitalSan FranciscoCaliforniaUSA
| | - Cameron Hicks
- Department of Urology, Helen Diller Family Comprehensive Cancer CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Matthew R. Cooperberg
- Department of Urology, Helen Diller Family Comprehensive Cancer CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
- Department of Epidemiology & BiostatisticsUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Peter R. Carroll
- Department of Urology, Helen Diller Family Comprehensive Cancer CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| |
Collapse
|
2
|
Merino Martinez R, Müller H, Negru S, Ormenisan A, Arroyo Mühr LS, Zhang X, Trier Møller F, Clements MS, Kozlakidis Z, Pimenoff VN, Wilkowski B, Boeckhout M, Öhman H, Chong S, Holzinger A, Lehtinen M, van Veen EB, Bała P, Widschwendter M, Dowling J, Törnroos J, Snyder MP, Dillner J. Human exposome assessment platform. Environ Epidemiol 2021; 5:e182. [PMID: 34909561 PMCID: PMC8663864 DOI: 10.1097/ee9.0000000000000182] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 11/14/2021] [Indexed: 11/26/2022] Open
Abstract
The Human Exposome Assessment Platform (HEAP) is a research resource for the integrated and efficient management and analysis of human exposome data. The project will provide the complete workflow for obtaining exposome actionable knowledge from population-based cohorts. HEAP is a state-of-the-science service composed of computational resources from partner institutions, accessed through a software framework that provides the world's fastest Hadoop platform for data warehousing and applied artificial intelligence (AI). The software, will provide a decision support system for researchers and policymakers. All the data managed and processed by HEAP, together with the analysis pipelines, will be available for future research. In addition, the platform enables adding new data and analysis pipelines. HEAP's final product can be deployed in multiple instances to create a network of shareable and reusable knowledge on the impact of exposures on public health.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Frederik Trier Møller
- Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
| | | | - Zisis Kozlakidis
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Ville N. Pimenoff
- Karolinska Institutet, Stockholm, Sweden
- Faculty of Medicine, University of Oulu, Oulu, Finland
- Tampere University, Tampere, Finland
| | | | | | - Hanna Öhman
- Faculty of Medicine, University of Oulu, Oulu, Finland
- Biobank Borealis of Northern Finland, Oulu University Hospital, Oulu, Finland
| | - Steven Chong
- Danish National Biobank, Statens Serum Institut, Copenhagen, Denmark
| | | | - Matti Lehtinen
- Karolinska Institutet, Stockholm, Sweden
- Tampere University, Tampere, Finland
| | | | | | - Martin Widschwendter
- Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria
| | | | | | | | | |
Collapse
|